Cue biopharma's therapeutic immuno-stat biologics to be featured in oxford university presentation at the 67th biophysical society annual meeting

Boston, feb. 16, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today that the company's therapeutic immuno-stat™ (selective targeting and alteration of t cells) platform and biologics will be featured in a poster at the 67th biophysical society annual meeting, taking place february 18-22, 2023 in san diego, ca. the research is part of a strategic research collaboration that cue biopharma initiated with dr. michael dustin's laboratory at the university of oxford in may 2020 to determine the molecular mechanisms underlying the activity of the company's interleukin 2 (il-2) based cue-100 series of biologics.
CUE Ratings Summary
CUE Quant Ranking